Shares of Hologic (NASDAQ:HOLX) were unchanged in after-market trading after the company reported Q3 results.
Earnings per share were up 19.05% over the past year to $0.75, which beat the estimate of $0.37.
Revenue of $822,900,000 decreased by 3.46% year over year, which beat the estimate of $607,710,000.
Q4 EPS expected between $0.95 and $1.15.
Q4 revenue expected between $925,000,000 and $1,025,000,000.
Details Of The Call
Date: Jul 29, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/e9eoejo2
Company's 52-week high was at $63.60
52-week low: $26.49
Price action over last quarter: Up 38.70%
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.
See more from Benzinga
- Earnings Scheduled For July 29, 2020
- Hologic's Earnings Outlook
- Stocks That Hit 52-Week Highs On Thursday
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.